Stock analysts at Barclays initiated coverage on shares of PRA Health Sciences (NASDAQ:PRAH) in a report issued on Monday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $94.00 price target on the medical research company’s stock. Barclays’ target price indicates a potential upside of 12.24% from the company’s previous close.

PRAH has been the topic of several other reports. Raymond James Financial began coverage on shares of PRA Health Sciences in a report on Wednesday, August 16th. They issued an “outperform” rating and a $89.00 price target on the stock. Zacks Investment Research upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $83.00 price objective for the company in a research report on Tuesday, August 15th. SunTrust Banks reissued a “buy” rating and issued a $101.00 price target on shares of PRA Health Sciences in a research note on Friday, October 27th. Mizuho began coverage on shares of PRA Health Sciences in a research note on Thursday, September 21st. They issued a “buy” rating and a $82.00 price target for the company. Finally, Credit Suisse Group increased their price objective on shares of PRA Health Sciences from $90.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, October 26th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $89.50.

PRA Health Sciences (PRAH) traded up $1.04 on Monday, hitting $83.75. The stock had a trading volume of 503,499 shares, compared to its average volume of 526,221. PRA Health Sciences has a 1 year low of $53.47 and a 1 year high of $84.38. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.01 and a quick ratio of 1.01. The stock has a market cap of $5,241.31, a PE ratio of 30.41, a P/E/G ratio of 1.43 and a beta of 0.40.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, beating the consensus estimate of $0.85 by $0.03. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The business had revenue of $494.55 million for the quarter, compared to the consensus estimate of $477.89 million. During the same period last year, the business posted $0.64 EPS. The company’s revenue was up 23.7% compared to the same quarter last year. research analysts expect that PRA Health Sciences will post 3.2 EPS for the current fiscal year.

In related news, Director Matthew P. Young sold 5,115 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $79.90, for a total transaction of $408,688.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.10% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Carroll Financial Associates Inc. grew its position in PRA Health Sciences by 127.4% during the third quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock worth $112,000 after buying an additional 790 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of PRA Health Sciences by 12.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after acquiring an additional 160 shares in the last quarter. Comerica Bank purchased a new stake in PRA Health Sciences during the 3rd quarter valued at $214,000. Trustmark National Bank Trust Department bought a new position in shares of PRA Health Sciences during the 2nd quarter valued at $225,000. Finally, Aperio Group LLC bought a new position in shares of PRA Health Sciences during the 2nd quarter valued at $233,000. Institutional investors and hedge funds own 98.49% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “PRA Health Sciences (PRAH) Research Coverage Started at Barclays” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/11/pra-health-sciences-prah-research-coverage-started-at-barclays.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.